Dr. Maude St-Onge completed her medical studies at Université de Montréal in 2006, specialized in Emergency Medicine at Laval University in 2011, and in Critical Care at the University of Toronto in 2013, and in Clinical Pharmacology and Toxicology at the University of Toronto, in 2016. Dr. St-Onge obtained a Master’s Degree in Public Health in 2004 and a Ph.D. in Medical Sciences in 2015 from the University of Toronto under the supervision of renowned scientists in the field of acute care, such as Dr. Laurie Morrison (scientist in emergency medicine), Dr. David Juurlink (clinician-scientist in toxicology) and Dr. Gorden Rubenfeld (clinician-scientist in critical care medicine). Her Ph.D. aimed at developing international recommendations for the management of calcium channel blocker poisoning and included a systematic review, a retrospective study, an economic study, a survey, and a Delphi.
Since July of 2015, Dr. Maude St-Onge has been the medical director of the Centre antipoison du Québec, works as an intensivist clinician-scientist at the CHU de Québec and as an assistant professor for the Department of Family Medicine and Emergency Medicine, as well as the Laval University Department of Anesthesiology and Critical Care Medicine. Scientist awarded by the FRQS working at the CHU de Québec – Laval University research center for the Population Health and Optimal Health Practice Research (Trauma – Emergency – Critical Care), Dr. St-Onge’s research interests concern acute care toxicology. She is currently studying the factors influencing adherence to the recommendations she developed during her Ph.D. (qualitative study, matched crossover study), evaluating the risks and benefits related to the administration of activated charcoal to poisoned patients (activated CHARcoal in Poisoned Patients – CHARPP: systematic review, retrospective study, survey, validation of a clinical score, pilot study, clinical trial), and working to better understand the continuum of care provided to Indigenous poisoned patients (CARe for Indigenous Poisoned Patients – CARIPP: scoping review, retrospective study, qualitative study). Indeed, activated charcoal is the most often recommended intervention by poison centres and the Indigenous population is the most affected by poisonings.
Data not available
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.Journal Article
Nat Med, 2021.
Acute health care among Indigenous patients in Canada: a scoping review.Journal Article
Int J Circumpolar Health, 80 (1), 2021.
Cardiovascular Drug Toxicity.Journal Article
Crit Care Clin, 37 (3), 2021.
To call or not to call: behavioral determinants influencing the decision of intensivists to consult poison centers for calcium channel blocker poisoning.Journal Article
Clin Toxicol (Phila), 58 (9), 2020.
Barriers and Facilitators of Intensivists' Adherence to Hyperinsulinemia-Euglycemia Therapy in the Treatment of Calcium Channel Blocker Poisoning.Journal Article
J Med Toxicol, 14 (4), 2018.
Bilateral nail gun traumatic brain injury presents as intentional overdose: A case report.Journal Article
CJEM, 20 (5), 2018.
Drug Administration to the Wrong Nursing Home Residents Reported to the Québec Poison Center: A Retrospective Study.Journal Article
J Am Med Dir Assoc, 19 (10), 2018.
Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline.Journal Article
BMJ, 361 , 2018.
Phenytoin overdose treated with hemodialysis using a high cut-off dialyzer.Journal Article
Hemodial Int, 21 (1), 2017.
BET 3: In septic patients requiring fluid resuscitation can the bedside lung ultrasound be used to assess the pulmonary fluid status?Journal Article
Emerg Med J, 34 (6), 2017.
- Utilisation du charbon activé chez les patients intoxiqués (CHARPP - Use of activated CHARcoal in Poisoned Patients), from 2016-07-01 to 2023-06-30
Recently finished projects
- Impact d'un Protocole de Prise en charge du Patient Intoxiqué par les Cardiotoxiques (IPPIC), from 2018-01-01 to 2019-12-31
- Transfusion in traumatic brain injury (TSiTBI Trial), from 2016-07-01 to 2021-06-30